undamentalytics Newsletter

Pace Gary W: insider trades

Director at 3 companies we cover. 18 open-market purchases and 12 sales not made under a pre-set plan, reported from February 23, 2010 to July 16, 2026.

Would copying Pace Gary W’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 10 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on November 25, 2011 into $4,059 by November 2, 2026, −5.9% a year. The copy held shares only 36% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $22,899, +5.7% a year (the S&P 500 held throughout made $84,434, +15.4% a year). Beta against the index was 0.49. Twelve months after each report, the average purchase was −20.8% against the S&P 500 (median −55.2%), and 20% beat it. Measured from the trade date, the insider’s own timing, the average was −17.0%. After their sales, the shares moved −4.9% against the index over 12 months on average (a negative figure means selling was the right call); 58% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$25.0k$50.0k$75.0k 20112013201520172019202120232025 $84.4k$22.9k$4.1k
Copying Pace Gary WS&P 500, same days investedS&P 500, held throughout $10,000 copying Pace Gary W’s open-market purchases from November 25, 2011, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−5.9%
S&P 500, same days invested
+5.7% (held throughout +15.4%)
Time in shares
36%
Sharpe ratio (S&P 500)
0.05 (0.84)
Biggest drop (S&P 500)
−95% (−34%)
Market sensitivity (beta)
0.49
Purchases copied
10

Trade by trade

Pace Gary W: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 10 +3.9% −20.8% 30% 6 0.96 0.38 No reliable evidence
Purchases, 6 months after the report 10 −15.0% −21.9% 30% 6 0.16 0.88 No reliable evidence
Purchases, 12 months after the report 10 −20.8% −55.2% 20% 6 0.27 0.80 No reliable evidence
Purchases, 12 months after the trade 10 −17.0% −34.2% 20% 6 0.44 0.68 No reliable evidence
Sales, 3 months after the report 12 −0.1% −0.2% 50% 10 −0.54 0.60 No reliable evidence
Sales, 12 months after the report 12 −4.9% −3.0% 58% 10 −1.28 0.23 No reliable evidence
Sales, 12 months after the trade 12 −3.7% −4.5% 58% 10 −1.14 0.28 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Cardiff Oncology, Inc. CRDF —130May 13, 2020July 16, 2026
ResMed| RMD —09February 23, 2010May 10, 2018
Pacira Biosciences, Inc. PCRX —53November 23, 2011March 8, 2024

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
July 16, 2026July 14, 2026 CRDF Purchase $1,003,436 not yetnot yetnot yet
June 22, 2026June 18, 2026 CRDF Purchase $36,600 not yetnot yetnot yet
July 31, 2025July 30, 2025 CRDF Purchase $710,500 not yetnot yetnot yet
December 12, 2024December 11, 2024 CRDF Purchase $940,199 not yetnot yetnot yet
March 8, 2024March 6, 2024 PCRX Sale $3,656,226 −12.2%−36.1%−34.7%
December 19, 2023December 19, 2023 CRDF Purchase $41,100 not yetnot yetnot yet
November 14, 2023November 10, 2023 CRDF Purchase $22,491 not yetnot yetnot yet
May 15, 2023May 11, 2023 PCRX Sale $209,527 −17.9%−54.4%−55.9%
September 19, 2022September 15, 2022 CRDF Purchase $256,500 not yetnot yetnot yet
March 1, 2022February 28, 2022 PCRX Sale $2,006,150 −4.8%−34.8%−26.8%
September 22, 2021September 21, 2021 CRDF Purchase $202,500 −23.2%−62.7%−62.7%
March 24, 2021March 23, 2021 CRDF Purchase $102,300 −38.1%−92.4%−91.5%
March 19, 2021March 18, 2021 CRDF Purchase $31,660 −34.0%−92.3%−88.7%
March 4, 2021March 4, 2021 CRDF Purchase $13,905 −32.5%−90.0%−91.2%
September 17, 2020September 16, 2020 CRDF Purchase $14,526 +139.1%−57.3%−18.1%
May 13, 2020May 11, 2020 CRDF Purchase $600,000 not yetnot yetnot yet
November 21, 2018November 19, 2018 PCRX Purchase $207,810 −19.6%−23.8%−21.9%
November 9, 2018November 7, 2018 PCRX Purchase $205,160 −19.2%−27.0%−26.0%
May 10, 2018May 8, 2018 RMD Sale $2,765,600 +1.4%+5.6%+7.1%
August 22, 2016August 19, 2016 RMD Sale $2,517,480 −13.6%−1.9%−6.5%
March 17, 2015March 13, 2015 PCRX Purchase $93,830 −21.9%−53.0%−42.3%
January 28, 2015January 26, 2015 RMD Sale $3,204,960 −1.8%−6.1%−4.8%
August 20, 2014August 18, 2014 RMD Sale $1,290,000 −2.3%+2.4%+0.5%
February 20, 2014February 18, 2014 RMD Sale $2,210,880 +7.1%+28.1%+29.7%
August 9, 2012August 7, 2012 RMD Sale $1,728,000 +12.9%+15.5%+19.3%
April 17, 2012April 17, 2012 PCRX Purchase $97,500 +54.6%+177.5%+172.0%
January 31, 2012January 27, 2012 RMD Sale $1,440,000 +13.8%+38.3%+40.8%
November 23, 2011November 21, 2011 PCRX Purchase $49,998 +33.6%+112.6%+100.6%
June 23, 2011June 22, 2011 RMD Sale $1,994,240 +5.4%−4.1%−4.2%
February 23, 2010February 19, 2010 RMD Sale $1,830,720 +10.1%−11.1%−9.3%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Pace Gary W traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.